Irene Mukui, MBChB

Head of HIV, Drugs for Neglected Disease Initiative

Dr. Irene Mukui, MBChB, is currently the Head of HIV at Drugs for Neglected Disease Initiative (https://dndi.org/). She is a medical epidemiologist with over 17 years’ experience in clinical and health programme management. She holds a Bachelor of Medicine and Bachelor of Surgery degree from the University of Nairobi and an MPH in Epidemiology from the University of Washington in Seattle, USA. She is an alumni of the Fogarty Global Health Fellowship (2018-2019) supported by the Northern Pacific Global Research Fellow Training Consortium with funding from Fogarty International Center of the National Institutes of Health. Dr. Mukui previously served in various leadership roles in the Ministry of Health in Kenya having been the Deputy Head of the ministry’s Universal Health Coverage Secretariat, and prior to that the Deputy Head of the National AIDS and STI Control Programme and Programme Manager for HIV Care and Treatment and Pre-Exposure Prophylaxis. She has contributed widely to the global HIV response having been a member of WHO HIV treatment Guidelines Development Group for many years, co-chair of the WHO HIV Drug Resistance Steering Group, and she is a member of multiple other HIV working groups. Dr. Mukui has been involved in implementation research across HIV prevention and treatment with her current focus being on pediatric HIV treatment and outcomes, mental health among HIV infected adolescents, and HIV drug resistance.

Publications

  1. Mukui, I, Peacock, S, Donnell, D, Gati-Mirembe, B, Krows, M, Bukusi, EA et al.. High prevalence and incidence of curable sexually transmitted infections among young women using oral HIV pre-exposure prophylaxis in sub-Saharan Africa: results from the INSIGHT Cohort study. Sex Transm Infect. 2025; :. doi: 10.1136/sextrans-2025-056625. PubMed PMID:41448908 .
  2. Parikh, UM, Kudrick, LD, Levy, L, Bosek, E, Chohan, BH, Mukui, I et al.. A cross-sectional study evaluating the frequency of HIV drug resistance mutations among individuals diagnosed with HIV-1 in tenofovir disoproxil fumarate-based pre-exposure prophylaxis rollout programmes in Kenya, Zimbabwe, Eswatini and South Africa. J Int AIDS Soc. 2025;28 (8):e70011. doi: 10.1002/jia2.70011. PubMed PMID:40836601 PubMed Central PMC12367864.
  3. List, K, Agamile, P, Alia, DY, Cherutich, P, Danforth, K, Kinuthia, J et al.. Reimagining policy implementation science in a global context: a theoretical discussion. Front Health Serv. 2024;4 :1292688. doi: 10.3389/frhs.2024.1292688. PubMed PMID:39371575 PubMed Central PMC11449972.
  4. Patel, RC, Oyaro, P, Thomas, KK, Basha, GW, Wagude, J, Mukui, I et al.. Impact of point-of-care HIV viral load and targeted drug resistance mutation testing on viral suppression among Kenyan pregnant and postpartum women: results from a prospective cohort study (Opt4Mamas). J Int AIDS Soc. 2023;26 (11):e26182. doi: 10.1002/jia2.26182. PubMed PMID:37938856 PubMed Central PMC10631517.
  5. Abuogi, L, Oyaro, P, Wakjira, G, Thomas, KK, Scallon, AJ, Mukui, I et al.. HIV Drug Resistance Patterns and Characteristics Associated with Clinically Significant Drug Resistance among Children with Virologic Failure on Antiretroviral Treatment in Kenya: Findings from the Opt4Kids Randomized Controlled Trial. Viruses. 2023;15 (10):. doi: 10.3390/v15102083. PubMed PMID:37896860 PubMed Central PMC10612029.
Search PubMed

Comments are closed.